GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » K Pharma Inc (TSE:4896) » Definitions » Total Long-Term Assets

K Pharma (TSE:4896) Total Long-Term Assets : 円5 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is K Pharma Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. K Pharma's Total Long-Term Assets for the quarter that ended in Mar. 2024 was 円5 Mil.


K Pharma Total Long-Term Assets Historical Data

The historical data trend for K Pharma's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

K Pharma Total Long-Term Assets Chart

K Pharma Annual Data
Trend Dec21 Dec22 Dec23
Total Long-Term Assets
1.08 3.64 4.93

K Pharma Quarterly Data
Dec21 Dec22 Jun23 Sep23 Dec23 Mar24
Total Long-Term Assets Get a 7-Day Free Trial 3.64 3.64 3.64 4.93 4.93

K Pharma Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.


K Pharma Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of K Pharma's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


K Pharma (TSE:4896) Business Description

Traded in Other Exchanges
N/A
Address
7-7-7 Roppongi, Minato-ku, Tokyo, JPN, 106-0032
K Pharma Inc is a company involved in Research, development, manufacturing, sales and marketing of pharmaceutical products and regenerative medicine products. It is involved in studying of iPs cells in regnerative medecine to treat neurological conditions such as cerebral infarction and SCI.

K Pharma (TSE:4896) Headlines

No Headlines